Biotinylated Human CD8 alpha&beta (CD8A&CD8B) Heterodimer Protein, His,Avitag™&Tag Free (MALS verified)
分子别名（Synonym）
CD8 alpha & beta, CD8A & CD8B
表达区间及表达系统（Source）
Biotinylated Human CD8A&CD8B Heterodimer Protein, His,Avitag&Tag Free (CDA-H82W7) is expressed from human 293 cells (HEK293). It contains AA Ser 22 - Asp 182 & Leu 22 - Pro 170 (Accession # P01732 & P10966-1).
Predicted N-terminus: Ser 22 & Leu 22
蛋白结构（Molecular Characterization）
The protein has a calculated MW of 26.0 kDa & 22.1 kDa. The protein migrates as 33 kDa and 35 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.
标记（Labeling）
Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.
蛋白标记度（Protein Ratio）
Passed as determined by the HABA assay / binding ELISA.
内毒素（Endotoxin）
Less than 0.1 EU per μg by the LAL method / rFC method.
纯度（Purity）
>90% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.
制剂（Formulation）
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
重构方法（Reconstitution）
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存储（Storage）
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.
背景介绍
CD8A是一种重要的膜整合糖蛋白，在免疫应答中发挥核心作用，针对外界侵袭和内部异常具有多重防御功能。该蛋白与CD8B在细胞表面形成二硫键连接的异源二聚体。CD8A同源二聚体分子还能促进活化淋巴细胞的存活，并推动其分化为记忆性CD8 T细胞。此外，CD8B在CD8+ T细胞的胸腺选择过程中起关键作用——其胞质尾端的棕榈酰化位点有助于CD8定位于富含信号蛋白的质膜脂筏区域。
关键字： CD8A&CD8B;CD8A蛋白;CD8B重组蛋白;ACRO;百普赛斯;
百普赛斯集团ACROBiosystems Group（股票代码：301080）是成立于2010年的跨国生物科技公司，是为全球生物医药、健康产业领域提供关键生物试剂产品及解决方案的行业平台型基石企业。2021年在创业板上市。百普赛斯集团业务遍布全球，横跨亚洲、北美洲、欧洲，在中国、美国、瑞士等12个城市设有办公室、研发中心及生产基地。目前累计服务客户超6000家，与全球Top 20医药企业均建立了长期、稳定的合作伙伴关系。集团旗下拥有品牌ACROBiosystems百普赛斯、bioSeedin柏思荟、Condense Capital垦拓资本和ACRODiagnostics百斯医学等。